Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 12, Issue 5, 2014, Pages 317-324

  Sonpavde, Guru ^a   Pond, Gregory R ^b   Armstrong, Andrew J ^c   Clarke, Stephen J ^d   Vardy, Janette L ^d   Templeton, Arnoud J ^d   Wang, Shaw Ling ^e,f   Paolini, Jolanda ^e   Chen, Isan ^e,g   Chow Maneval, Edna ^e,g   Lechuga, Mariajose ^e   Smith, Matthew R ^h,i   Dror Michaelson, M ^h,i  

^a University of Alabama at Birmingham   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PFIZER INC   (United States)

^f ICON CLINICAL RESEARCH   (United States)

^g Aragon Pharmaceuticals   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Advanced prostate cancer; Lymphocytes; Neutrophils; Prognosis; Survival

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; DOCETAXEL; HEMOGLOBIN; LACTATE DEHYDROGENASE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SUNITINIB; TRANSCRIPTION FACTOR PAX5; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VALIDATION STUDY; BLOOD; CLINICAL TRIAL; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; KAPLAN MEIER METHOD; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HEMOGLOBINS; HUMANS; INDOLES; INFLAMMATION; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PLACEBOS; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRROLES; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84922624360     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.03.005     Document Type: Article

References (48)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22
2. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16:5805-13
3. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-tolymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012; 79: 1085-91
4. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012; 187:411-7
5. Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophillymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17:216-22
6. Sejima T, Iwamoto H, Morizane S, et al. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. Urol Oncol 2013; 31:1343-9
7. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58:15-23
8. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011; 104:504-10
9. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88:218-30
10. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-9
11. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13:6396-403
12. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25
13. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10:233-9
14. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer [published correction appears in Clin Cancer Res 2009; 15:1506]. Clin Cancer Res 2008; 14:6302-9
15. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-7
16. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16:203-11
17. Scher HI, Heller G, Molina GA, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29(suppl):abstract LBA4517
18. Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014; 32:76-82
19. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol 2008; 26:1148-59
20. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-35
21. Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophiltolymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel [e-pub ahead of print]. BJU Int doi: 10.1111/bju.12531, accessed October 29, 2013
22. Keizman D, Gottfried M, Ish-Shalom M, et al. Pretreatment neutrophil-tolymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 2012; 17:1508-14
23. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27:4709-17
24. Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012; 48:202-8
25. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47:2633-41
26. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 2013. http://dx.doi.org/10.1016/j.suronc.2013.12.001
27. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 2012; 36:617-22
28. Leibowitz-Amit R, Templeton AJ, Omlin A, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25:657-62
29. Ilie M, Hofman V, Ortholan C, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonesmall cell lung cancer. Cancer 2012; 118:1726-37
30. Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 2001; 49:63-9
31. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134:1325-31 [discussion 31-2]
32. McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol 2001; 27:396-403
33. Celikbilek M, Dogan S, Yurci A, Ozbakir O. Neutrophil to lymphocyte ratio: a hopeful marker predicting the disease severity in patients with nonalcoholic fatty liver disease. Liver Int 2012; 32:1188 [author reply 1189-90]
34. Azab B, Daoud J, Naeem FB, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail 2012; 34:571-6
35. Azab B, Jaglall N, Atallah JP, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 2011; 11:445-52
36. Ergelen M, Uyarel H, Altay S, et al. Predictive value of elevated neutrophil to lymphocyte ratio in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2013. http://dx.doi. org/10.1177/1076029612473516
37. Ertas G, Sonmez O, Turfan M, et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J Neurol Sci 2013; 324:49-52
38. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 2012; 30:33-7
39. Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005; 66:386-91
40. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7:1932-6
41. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161:182-7
42. Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int 2012; 110:E461-8
43. Lucarelli G, Ditonno P, Bettocchi C, et al. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol 2013; 9:899-907
44. Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 2013; 11:423-30
45. Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. J Clin Oncol 2013; 13(suppl):abstract 5013
46. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
47. Halabi S, Lin CY, Small EJ, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013; 105:1729-37
48. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23:9067-72.